“Thank you so much for your invaluable assistance in securing my approvals.”

Case Summary:

When it comes to tackling mental health disorders, innovation happens at the molecular level. One exceptional biomedical researcher from Poland, whose work merges neuroimmune biomarkers, machine learning, and psychiatric diagnostics, has recently achieved a major immigration milestone: approval of both the NIW and EB1A I-140 petitions, despite receiving a Request for Evidence (RFE) on the latter. Our team had the privilege of representing this trailblazer through both filings, culminating in a dual approval on May 1, 2025.

A Career Rooted in Precision Psychiatry

The scientist’s expertise lies in developing blood-based and digital biomarker diagnostics for complex mental illnesses such as schizophrenia and bipolar disorder. By using cutting-edge analytics to probe immune system behavior, he has devised methods for earlier diagnosis, treatment personalization, and even drug discovery, especially for cases where traditional psychiatric models fall short.

Currently employed in a senior research capacity at a UK medical research institution, he continues to lead pioneering studies at the intersection of molecular psychiatry, artificial intelligence, and healthcare delivery.

Evidence that Mattered: A Record of Real Impact

Across both the NIW and EB1A petitions, we presented compelling evidence of the client’s far-reaching influence:

● 35 peer-reviewed journal articles, 14 of them first- or co-first-authored

● 1257 citations and an h-index of 17, placing him in the top 4% of authors in psychiatry

● Over 40 completed peer reviews for journals like Molecular Psychiatry, Biological Psychiatry, and Frontiers in Psychiatry, where he also serves as an editorial board member

● Extensive international funding from leading research bodies, including the UK’s Medical Research Council and the EU Framework Programmes

Twelve of his articles rank in the top 10% most cited for their year and field, underscoring their relevance and ongoing use by global peers.

The Science Behind the Approval

Among his most groundbreaking studies is a cytokine-based framework that isolates interleukin-10 as a therapeutic target for schizophrenia. Another major contribution is a machine learning algorithm that accurately distinguishes between bipolar disorder and major depressive disorder—a feat that has reshaped how clinical teams handle early diagnosis.

In support of the EB1A, one recommender noted:

“His methodologies have set a new standard in biomarker research, with immediate implications for both academic investigation and translational medicine. His integration of machine learning with immunoassays is nothing short of pioneering.”

In both petitions, we argued not only that his research has “substantial merit and national importance” (NIW) but also that his contributions rise to the level of “extraordinary ability” (EB1A), supported by global citation, editorial service, high-impact publishing, and thought leadership in psychiatric innovation.

Dual Approval, One Vision

While many applicants pursue the NIW or EB1A individually, this client’s extraordinary profile justified the parallel pursuit of both categories. As a result, he received a rare same-day approval for both petitions, marking a significant validation of his impact in biomedical science and his future contributions to U.S. healthcare and scientific leadership.

We are honored to have assisted this visionary researcher through both pathways and look forward to the next chapter of his work—developing technologies that can detect, treat, and perhaps even prevent the most elusive mental health conditions of our time.